Surveillance in Patients With Barrettʼs Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis

Abstract Background: The prevalence of type 2 diabetes mellitus (T2DM) is growing in China. Both physical and psychological complications occur along with the development of T2DM. The patients with depression account for a significant proportion of T2DM. Depressive symptoms interfere with blood glucose management, leading to poorer treatment outcome and even relate to the occurrence of other serious complications of T2DM population. Among these T2DM patients with depression, early detection and treatment is essential and effective. Knowledge of the current prevalence of depression in T2DM patients as well as associated risk factors may be meaningful for healthcare planning. Therefore, we plan to conduct a systematic review and meta-analysis to evaluate the Chinese prevalence of depression in T2DM and explore associated risk factors.Methods: We will search literatures recorded in MEDLINE/PubMed, EMBASE, the Cochrane Library, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang database (Wanfang Data). The grey literatures and reference list will be manually searched. We will include population-based, cross-sectional surveys that investigated the Chinese prevalence of depression in T2DM or/and researched the possible risk factors. Two reviewers will screen studies, extract data and evaluate quality independently. We will assess inter-rater agreement between reviewers for study inclusion, data extraction, and study quality assessment using Kappa statistics. The primary outcome will be the pooled Chinese prevalence of depression in T2DM patients. The secondary outcome will contain the potential risk factors for depression in patients with T2DM. R software (version 3.6.1) and STATA software (version 12) will be used for data analysis.Discussion: This systematic review will provide comprehensive evidence of the Chinese prevalence and risk factors of depression in patients with T2DM. we expect to provide evidence basis for healthcare practitioners and policy makers to pay attention to the mental health of T2DM. Our data will highlight the need and importance of early detection and intervention for depression in patients with T2DM. Systematic review registration: PROSPERO CRD42020182979.

Download Full-text

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis

Frontiers in Oncology ◽

10.3389/fonc.2021.649171 ◽

2021 ◽

Vol 11 ◽

Author(s):

Jiale Sun ◽

Yuxin Lin ◽

Xuedong Wei ◽

Jun Ouyang ◽

Yuhua Huang ◽

...

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Early Detection ◽

Publication Bias ◽

Detection Rate ◽

Meta Analysis ◽

Cochrane Library ◽

Recurrent Prostate Cancer ◽

Pet Ct ◽

Statistical Heterogeneity

Background: Prostate-specific membrane antigen (PSMA)-targeted 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography/computed tomography (PET/CT) has shown advantages in primary staging, restaging, and metastasis detection of prostate cancer (PCa). However, little is known about the role of 18F-DCFPyL PET/CT in biochemically recurrent prostate cancer (BRPCa). Hence, we performed a systematic review and meta-analysis to evaluate 18F-DCFPyL PET/CT as first-line imaging modality in early detection of BRPCa.Methods: A comprehensive literature search of PubMed, Web of Science, Embase, and Cochrane Library was conducted until December 2020. The pooled detection rate on a per-person basis and together with 95% confidence interval (CI) was calculated. Furthermore, a prostate-specific antigen (PSA)-stratified performance of detection positivity was obtained to assess the sensitivity of 18F-DCFPyL PET/CT in BRPCa with different PSA levels.Results: A total of nine eligible studies (844 patients) were included in this meta-analysis. The pooled detection rate (DR) of 18F-DCFPyL PET/CT in BRPCa was 81% (95% CI: 76.9–85.1%). The pooled DR was 88.8% for PSA ≥ 0.5 ng/ml (95% CI: 86.2–91.3%) and 47.2% for PSA < 0.5 ng/ml (95% CI: 32.6–61.8%). We also noticed that the regional lymph node was the most common site with local recurrence compared with other sites (45.8%, 95% CI: 42.1–49.6%). Statistical heterogeneity and publication bias were found.Conclusion: The results suggest that 18F-DCFPyL PET/CT has a relatively high detection rate in BRPCa. The results also indicate that imaging with 18F-DCFPyL may exhibit improved sensitivity in BRPCa with increased PSA levels. Considering the publication bias, further large-scale multicenter studies are warranted for validation.

Download Full-text

Development of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus and High Grade Dysplasia Undergoing Survilence: A Meta-Analysis and Systematic Review

Gastrointestinal Endoscopy ◽

10.1016/j.gie.2006.03.030 ◽

2006 ◽

Vol 63 (5) ◽

pp. AB82 ◽

Cited By ~ 4

Author(s):

Srinivas R. Puli ◽

Amit Rastogi ◽

Sharad Mathur ◽

Ajay Bansal ◽

Prateek Sharma

Keyword(s):

Systematic Review ◽

Barrett’S Esophagus ◽

Esophageal Adenocarcinoma ◽

Barrett's Esophagus ◽

Meta Analysis ◽

High Grade Dysplasia ◽

High Grade

Download Full-text

Utility of the methylated SEPT9 test for the early detection of colorectal cancer: a systematic review and meta-analysis of diagnostic test accuracy

BMJ Open Gastroenterology ◽

10.1136/bmjgast-2019-000355 ◽

2020 ◽

Vol 7 (1) ◽

pp. e000355 ◽

Cited By ~ 5

Author(s):

Rohit Hariharan ◽

Mark Jenkins

Keyword(s):

Colorectal Cancer ◽

Systematic Review ◽

Early Detection ◽

Positive Predictive Value ◽

Negative Predictive Value ◽

Diagnostic Test ◽

Predictive Value ◽

Meta Analysis ◽

Test Accuracy ◽

Sensitivity Specificity

BackgroundCirculating tumour DNA from colorectal cancer (CRC) is a biomarker for early detection of the disease and therefore potentially useful for screening. One such biomarker is the methylated SEPT9 (mSEPT9) gene, which occurs during CRC tumourigenesis. This systematic review and meta-analysis aims to establish the sensitivity, specificity and accuracy of mSEPT9 tests for the early diagnosis of CRC.MethodsA systematic search of the relevant literature was conducted using Medline and Embase databases. Data were extracted from the eligible studies and analysed to estimate pooled sensitivity, specificity and diagnostic test accuracy.ResultsBased on 19 studies, the pooled estimates (and 95% CIs) for mSEPT9 to detect CRC were: sensitivity 69% (62–75); specificity 92% (89–95); positive likelihood ratio 9.1 (6.1–13.8); negative likelihood ratio 0.34 (0.27–0.42); diagnostic OR 27 (15–48) and area under the curve 0.89 (0.86–0.91). The test has a positive predictive value of 2.6% and negative predictive value of 99.9% in an average risk population (0.3% CRC prevalence), and 9.5% (positive predictive value) and 99.6% (negative predictive value) in a high-risk population (1.2% CRC prevalence).ConclusionThe mSEPT9 test has high specificity and moderate sensitivity for CRC and is therefore a potential alternative screening method for those declining faecal immunochemical test for occult blood (FIT) or other screening modalities. However, it is limited by its poor diagnostic performance for precancerous lesions (advanced adenomas and polyps) and its relatively high costs, and little is known about its acceptability to those declining to use the FIT.

Download Full-text

Corrigendum to “Role of leptin as a biomarker for early detection of renal cell carcinoma? No evidence from a systematic review and meta-analysis” [Med. Hypotheses 129 (2019) 1–6]

Medical Hypotheses ◽

10.1016/j.mehy.2019.109284 ◽

2019 ◽

Vol 131 ◽

pp. 109284

Author(s):

Komathi Perumal ◽

Weng Kit Huin ◽

Ning Yi Yap ◽

Teng Aik Ong ◽

Glenda Carolyn Gobe ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Early Detection ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis

Download Full-text

Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers

Cancer Cytopathology ◽

10.1002/cncy.22018 ◽

2018 ◽

Vol 126 (7) ◽

pp. 447-460 ◽

Cited By ~ 21

Author(s):

Megan A. Clarke ◽

Nicolas Wentzensen

Keyword(s):

Systematic Review ◽

Early Detection ◽

Meta Analysis ◽

Hpv Testing

Download Full-text

Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: A systematic review and meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.3_suppl.11 ◽

2014 ◽

Vol 32 (3_suppl) ◽

pp. 11-11

Author(s):

Preet Paul Singh ◽

Siddharth Singh ◽

Sushil Kumar Garg ◽

Prasad G. Iyer ◽

Hashem El-Serag

Keyword(s):

Systematic Review ◽

Cohort Studies ◽

Barrett’S Esophagus ◽

Esophageal Adenocarcinoma ◽

Barrett's Esophagus ◽

Observational Studies ◽

Meta Analysis ◽

Number Needed To Treat ◽

Case Control Studies ◽

Inconsistency Index

11 Background: Acid-suppressive medications, particularly proton pump inhibitors (PPI), may modify risk of esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE). We performed a systematic review and meta-analysis of studies evaluating the association between PPIs and histamine receptor antagonists (H2RA) and risk of EAC or high-grade dysplasia (BE-HGD) in patients with BE. Methods: Through a systematic search up to June 2013, we identified 7 observational studies (5 cohort studies and 2 case-control studies; 2,813 patients with BE, 317 cases of EAC and/or BE-HGD, 84.4% PPI users) reporting the association between PPIs or H2RA and EAC in patients with BE. Summary odds ratio (OR) with 95% confidence intervals (CI) was estimated using random effects model, and heterogeneity was measured using the inconsistency index (I2). Results: On meta-analysis, PPI use was associated with 71% reduction in EAC risk in patients with BE (adjusted OR, 0.29; 95% CI, 0.12-0.71). There was a trend toward a dose-response relationship with PPI use for >2 years protective against EAC [3 studies; PPI use >2 years vs. <2 years (as compared to no use): OR, 0.45 (0.19-1.06) vs. 1.09 (0.47-2.56)]. Considerable heterogeneity was observed in the overall analysis (I2=81%). On restricting analysis to 5 cohort studies, use of PPIs was consistently associated with a lower risk of EAC and/or BE-HGD (adjusted OR, 0.33; 95% CI, 0.19-0.58; I2=9%). H2RA use was not associated with decreased risk of EAC in patients with BE based on 2 studies (adjusted OR, 1.15; 95% CI, 0.77-1.72). Using a 67% summary risk reduction (derived from cohort studies) of EAC and/or BE-HGD with PPI use in patients with BE, and observed cumulative incidence rates of EAC and/or BE-HGD in patients with BE overall as 10.2 per 1,000 patient years, we estimate the number needed to treat with PPIs to prevent 1 case of EAC or BE-HGD in BE patients at 147. Conclusions: Based on meta-analysis of observational studies, the use of PPI, but not H2RA appears to be associated with a decreased risk of EAC and/or BE-HGD in patients with BE. PPI use should be considered in BE, and chemopreventive trials of PPIs in patients with BE are warranted.

Download Full-text